31Jan 2017

BIOLOGIC AND MORPHOLOGIC MARKERS OF THE THR OMEMBOLIC RISK IN THE ATRIAL FIBRILLATION

  • Service de cardiologie Hopital Militaire Avicenne. CHU Mohammed VI Marrakech.
Crossref Cited-by Linking logo
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Atrial fibrillation (AF) is the most common arrhythmia, In certain case he can expose to systemic thrombo-embolic complications. Antithrombotic treatment, with anticoagulant or antiplatelet agents is guided by the evaluation of the ischaemic and haemorrhagic risk based on validated clinical risk scores. However, these scores have limitations and their diagnostic performances are variable, which limit their use in daily practice ; Many biomarkers and morphologic markers have been Studied to refine the stratification of thrombo-embolic risk, and should be able to predict a more focused and more rational prescription of anticoagulant treatment.

  1. Fang MC, Go AS, Chang Y et al (2008). Comparison of risk strati?cation schemes to predict throm-boembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008;51:810?5
  2. Wilke T, Groth A, et al (2012). Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012;107:1053-65.
  3. Sadanaga T, Kohsaka S, Ogawa S (2010). D-dimer levels in combina-tion with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology 2010;117:31-6.i
  4. Roldan V, Marin F, Garcia-Herola A, Lip GY(2005). Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratifcation scores in atrial Fibrillation. Thromb Res 2005;116:321-5
  5. Watson T, Shantsila E, Lip GY(2005). Mechanisms of thrombogenesis in atrial fibrillation: Virchow?s triad revisited. Lancet 2009;373:155-66.
  6. Nozawa T,? Inoue? H,? Hirai? T,? et? al(2006).? d-dimer level? influences? thromboembolic? events? in? patients? with? atrial? Int? J? Cardiol? 2006;109:59?65
  7. Sadanaga T,? Sadanaga? M,? Ogawa? S(2010).? Evidence? that? d-dimer? levels? predict? subsequent? thromboembolic? and? cardiovascular? events? in? patients? withatrial? fibrillation? during? oral? anticoagulant? ? J? Am? Coll? Cardiol? 2010;55:2225?31
  8. Lip GY, Patel JV, Hughes E, Hart RG(2007). High-sensitivity c-reactive protein and soluble CD40 ligand as indices of infflammation and platelet activation in 880 patients with non valvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007;38:1229?37.
  9. Hijazi Z, Oldgren J, Andersson U, et al(2012). Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 2012;125:1605?16.
  10. Barra S, Almeida I, Caetano F, et al(2013). Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thromb Res 2013;132:293-9.
  11. Barra S, Almeida I, Caetano F et al(2013). Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thromb Res 2013;132:293-9
  12. Kleemann T, Becker T, et al(2009). Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr 2009;10:383
  13. Boyd AC, McKay T, Nasibi S,et al(2013). Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging 2013;14:269-75.
  14. The Stroke Pr?vention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. Ann Intern Med 1992;116:6-12
  15. Daccarett M, Badger T et al(2011). Association of LA fibrosis detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with atrial fibrillation. J Am Coll Cardiol 2011;57:831-8.
  16. Zabalgoitia M, Halperin JL, Pearce L et al(1998). Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 1998;31:1622?6.
  17. Heppell RM, Berkin KE, Mc Lenachan et al(1997). Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation. Heart 1997 ; 77 :407-11.
  18. Pongratz G, Brandt-Pohlmann M, Henneke KH, et al(1997). Platelet activation in embolic and preembolic status of patients with nonrheu-matic atrial fibrillation. Chest1997 ; 111 : 929-33
  19. Somloi M, Tomcsanyi J, Nagy E, et al(2003). D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation. Am J Cardiol2003 ; 92 : 85-7.
  20. Nakagawa K, Hirai T, Shinokawa N, et al(2002). Aortic spontaneous echocardiographic contrast and hemostatic markers in patients with non rheumatic atrial fibrillation. Chest2002 ; 121 : 500-5

[H. Jallal, A. Zbitou, S. Arioua, L. Bendriss and a. Khatouri. (2017); BIOLOGIC AND MORPHOLOGIC MARKERS OF THE THR OMEMBOLIC RISK IN THE ATRIAL FIBRILLATION Int. J. of Adv. Res. 5 (Jan). 2701-2707] (ISSN 2320-5407). www.journalijar.com

jallal hamid
3eme hopital militaire Laayoune maroc

DOI:

Article DOI: 10.21474/IJAR01/3062      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3062

Download Full Paper

Download PDF No. of Downloads: 6 | No. of Views: 69